Announces positive Phase 3 Panorama study results for DT120 ODT

What did Definium Therapeutics, Inc. announce?

Definium Therapeutics reported positive topline data from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder, meeting all primary and key secondary endpoints.

Key details

• DT120 ODT 100µg achieved a statistically significant reduction of 5.1 points in Hamilton Anxiety Rating Scale (HAM-A) score over placebo at Week 12 (p<0.0001).
• The study also showed statistically significant and clinically meaningful improvements in CGI-S at Day 2 and Week 12, and HAM-A at Week 1.
• DT120 ODT 100µg was generally well tolerated, with most adverse events being mild to moderate and transient; no new safety signals were identified.
• A pre-NDA meeting is scheduled for Q4 2026, with an NDA filing anticipated in H1 2027.

Why it matters

This 8-K reports a corporate disclosure at Definium Therapeutics, Inc.. The likely share-price reaction reads as positive.

More from Definium Therapeutics, Inc.

• 8-K

  Sep 8, 2026
  DT120 ODT receives second FDA Breakthrough Therapy designation for MDD

All Definium Therapeutics, Inc. SEC filings →